NCT02957032 is a Phase 1 clinical trial of F16IL2 in Acute Myeloid Leukemia, Relapsed, Adult, sponsored by Philogen S.p.A..

Who is sponsoring NCT02957032?

NCT02957032 is sponsored by Philogen S.p.A..

What drugs are being tested in NCT02957032?

Interventions in NCT02957032: F16IL2, cytarabine.

What condition does NCT02957032 study?

NCT02957032 studies Acute Myeloid Leukemia, Relapsed, Adult.

Is NCT02957032 still recruiting?

NCT02957032 is currently terminated. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT02957032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated Phase 1 Last updated 10 October 2023

What this trial tests

Phase 1 trial testing F16IL2 in Acute Myeloid Leukemia, Relapsed, Adult in 30 participants. Terminated before completion.

Timeline

13 April 2016

Primary endpoint
29 September 2023

29 September 2023

Quick facts

Lead sponsor	Philogen S.p.A.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	13 April 2016
Primary completion	29 September 2023
Estimated completion	29 September 2023
Sites	1 location across Germany

Drugs / interventions tested

F16IL2 — full drug profile →
cytarabine — full drug profile →

Conditions studied

Acute Myeloid Leukemia, Relapsed, Adult — all drugs for Acute Myeloid Leukemia, Relapsed, Adult →

Sponsor

Philogen S.p.A. — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia, Relapsed, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I, open label, non-randomized, multicenter, prospective dose escalation study of F16IL2 in combination with very low-dose cytarabine in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current progress in innovative engineered antibodies.
Strohl WR. · · 2018 · cited 169× · PMID 28822103 · DOI 10.1007/s13238-017-0457-8
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME, Sahin D, Karakus U, Boyman O. · · 2023 · cited 139× · PMID 37004361 · DOI 10.1016/j.ebiom.2023.104539
Engineering cytokine therapeutics.
Deckers J, Anbergen T, Hokke AM, de Dreu A, et al · · 2023 · cited 132× · PMID 37064653 · DOI 10.1038/s44222-023-00030-y
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.
Zheng X, Wu Y, Bi J, Huang Y, et al · · 2022 · cited 112× · PMID 35043005 · DOI 10.1038/s41423-021-00786-6
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
Murer P, Neri D. · · 2019 · cited 67× · PMID 30991144 · DOI 10.1016/j.nbt.2019.04.002
The present and future of immunocytokines for cancer treatment.
Gout DY, Groen LS, van Egmond M. · · 2022 · cited 41× · PMID 36066630 · DOI 10.1007/s00018-022-04514-9
Utilizing Immunocytokines for Cancer Therapy.
Runbeck E, Crescioli S, Karagiannis SN, Papa S. · · 2021 · cited 33× · PMID 33803078 · DOI 10.3390/antib10010010
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
Schürch CM. · · 2018 · cited 30× · PMID 29868474 · DOI 10.3389/fonc.2018.00152

Verify or expand the search:

Other trials of F16IL2

Trials testing the same drug.

NCT03207191 — Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopo · Phase 1 · completed

Other Philogen S.p.A. trials

Trials by the same sponsor.

NCT07120984 — A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutan · Phase 2 · not yet recruiting
NCT06640413 — A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L1 · Phase 1 · recruiting
NCT06840548 — A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer · Phase 1 · completed
NCT06840535 — A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer · Phase 1 · completed
NCT05784597 — A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02957032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philogen S.p.A.
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02957032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing